📰 Altor Bioscience News
Page 2 - Altor Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Altor Bioscience. Real-time updates on events, politics, business and more.
June 1, 2022
The increment in Checkpoint Inhibitor Refractory Cancer market size is due to high potency against cancer cells, increase in R&D activity, rise in the cases of types of cancers, where checkpoint
May 30, 2022
The increase in the LAG 3 Next Generation Immunotherapy market size is a direct consequence of the expected entry of premium LAG-3 drugs and their readily...
April 19, 2022
/PRNewswire/ -- The "Cancer Vaccines Global Market Report 2022: By Type, By Technology, By Cancer, By End-User" report has been added to...
April 19, 2022
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Cancer Vaccines Global Market Report 2022: By Type, By Technology, By Cancer, By End-User" report has...
April 13, 2022
The "Cancer Vaccines Global Market Report 2022: By Type, By Technology, By Cancer, By End-User" report has been added to ResearchAndMarkets.com's offe
April 13, 2022
DUBLIN--(BUSINESS WIRE)--The "Cancer Vaccines Global Market Report 2022: By Type, By Technology, By Cancer, By End-User" report has been added to ResearchAndMarkets.com's offering.The global cancer vaccines market is expected to grow from $4.47 billion in 2021 to $5.29 billion in 2022 at a compound annual growth rat...
February 25, 2022
A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.In addition, findings from the retrospective clinical case series suggested the biomarker test may detect disease recurrence earlier than imaging or other surveillance methods, allowing
February 13, 2022
Non–Muscle-Invasive Bladder Cancer (NMIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 20
February 13, 2022
Non–Muscle-Invasive Bladder Cancer (NMIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 20
December 8, 2021
Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround.